Global Gastrointestinal Stromal Tumor (GIST) Therapeutics Market is poised for a stable 6% CAGR from 2023 to 2033 | FMI

Gastrointestinal Stromal Tumor (GIST) Therapeutics Market
Gastrointestinal Stromal Tumor (GIST) Therapeutics Market

The global gastrointestinal stromal tumor (GIST) therapeutics market continues its upward trajectory, poised to reach a significant market value milestone. Forecasts suggest a remarkable surge, with expectations to garner a market value of US$ 890 Million in 2023, set to escalate further and accumulate a market value of US$ 1593 Million by 2033. This growth trajectory anticipates a commendable Compound Annual Growth Rate (CAGR) of 6% in the forecast period of 2023 to 2033.

Advances in healthcare and a growing number of treatment options for various illnesses, including cancer, have led to a higher life expectancy worldwide. Increased awareness of life-threatening conditions is also contributing to this trend. China, India, and Brazil are some of the fastest-growing nations in terms of their elderly populations and advances in healthcare are expected to further contribute to this growth. As a result, the market for GIST therapeutics is expected to grow during the forecast period.

Request A Sample Copy of This Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-16670

GIST therapeutics is expected to continue to grow in the coming years, driven by advances in research and development, increasing demand for effective treatments, and an aging patient population. Furthermore, North America and Asia Pacific are the two major regions contributing to the growth of the GIST therapeutics market owing to the increase in geriatric population across the regions.

Key Takeaways from the Market Study:

  • The Gastrointestinal stromal tumor (GIST) therapeutics market is expected to grow at a value of 6% CAGR in the forecast period 2023-2033.
  • By end user, hospitals are expected to hold 45% of the market share in 2023 for Gastrointestinal stromal tumor (GIST) therapeutics market.
  • North America is expected to possess 39% market share for Gastrointestinal stromal tumor (GIST) therapeutics market in 2023.
  • Asia Pacific Gastrointestinal stromal tumor (GIST) therapeutics market size is expected to possess 31% market share in 2023.

“Technological advancements along with development of different therapeutics treatments is creating lucrative opportunities for GIST therapeutics market.” states an FMI analyst

Get In Touch With Our Analyst To Resolve Any Doubts You May Have! https://www.futuremarketinsights.com/ask-question/rep-gb-16670

Competitive Landscape:

Key players in the gastrointestinal stromal tumor (GIST) therapeutics are Arog Pharmaceuticals, Taiho Pharmaceutical, Turning Point Therapeutics, Inc, Cogent Biosciences, Inc, Plexxikon Inc, Theseus Pharmaceuticals, Exelixis, Inc, Ipse, Bristol-Myers Squibb and Takeda

  • In August 2022, Taiho Pharmaceutical Co., Ltd. launched the oral heat shock protein (HSP) 90 inhibitor Jeselhy®tablets 40 mg (generic name: pimitespib) for GIST.
  • Turning Point Therapeutics, Inc, another key player in the GIST therapeutics market is focusing on researching and developing medication and is undergoing clinical trials to get the same approved for patients.

Key Segments Profiled in the Epidemic Keratoconjunctivitis Treatment Industry Survey:

By Drug Class:

  • Antihistamines
  • Anti-Inflammatory
  • Corticosteroids

By Route of Administration:

  • Topical
  • Oral

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Ignite Innovation with Customization: Uncover the Possibilities in Our Report! https://www.futuremarketinsights.com/customization-available/rep-gb-16670

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: 
sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these